Xizhi Technology and Mabwell Bioscience are preparing to launch initial public offerings in Hong Kong, with a goal of raising over $500 million.
These listings reflect the companies' ambitions to secure significant capital for their operations and growth.
The move to the Hong Kong market indicates a strategic decision by both firms to tap into the region's investment opportunities.